RN0361
Phase 2Small molecule
RN0361 is one of 37 small molecule programs targeting Adult. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
120 competitors in Adult
#DrugCompanyPhaseTrials
1Nydrazid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Tebrazid
AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Phase 3
Mounjaro
Eli LillyPhase 2
Rifampicin
Boehringer IngelheimPhase 3
Opzelura
DDizal Pharmaceuticals
Phase 2
Cabenuva
GSKPhase 1
NM8074
NNovelMed Therapeutics
Phase 2
Augtyro
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
Ansaid
PPharmacia and Upjohn
Phase 1
Hytrin
AAbbott
Phase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RN0361. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIkaria Bioscience Pty Ltd